Patricka Ott News Today

In a Phase 1 study among eight patients with advanced melanoma who received the NeoVax vaccine, after a median of four years, all of the patients remained alive and six patients had no signs of active disease.

Date Time Personalized vaccine produces long-lasting anti-tumor response in patients with melanoma, study shows Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and the Broad Institute of MIT and Harvard report in a new study. The findings, published online today by the ...

 E-Mail BOSTON - Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber Cancer Institute, Brigham and Womens Hospital, and the Broad Institute of MIT and Harvard report in a new study. The findings, published online today by the journal Nature Medicine, demonstrate the staying power of the immune response generated by the v...